投資人專區
Investor Relations
News and Updates
Our company is listed on the Emerging Stock Market and discloses significant information on a non-regular basis through the Market Observation Post System (MOPS). Please visit the Taiwan Stock Exchange's Market Observation Post System and enter the stock code 7731 to access the latest major announcements and related information of our company.
Financial Information
Operating Revenue
Unit: NT$ million
Investor Relations
Stock Code
7731Today's Stock Price
All stock quotation data on this webpage is provided for reference purposes only and should not be a basis for investment decisions. MARX Biotech is not responsible for any inaccuracies, delays in updates, or actions taken by readers in relation to the data. Any information on this webpage should not be reposted without permission.
Corporate Governance
Board of Directors Diversity
To enhance corporate governance and foster the robust development of the Board of Directors' composition and structure, the company promotes and values a diverse board policy. This policy, in accordance with Article 20 of the "Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies", encompasses various factors such as gender, age, nationality, culture, as well as professional knowledge and skills including professional background, expertise, and industry experience. The Company is committed to upholding this diversity policy.
The Company's current Board of Directors' diversity policy is implemented as follows:
Independence of the Board of Directors
The Company's current Board of Directors consists of 8 members. There are no circumstances among the Directors that fall under the provisions of Article 26-3, Paragraphs 3 and 4 of the Securities and Exchange Act.
Members of the Board of Directors
Chairman
Tse-Ping Dong
Education
Ph.D., College of Management, National Taiwan University
Master, College of Management, National Taiwan University
B.S., College of Science, National Taiwan University
Experience
Dean, College of Innovation and Industry, National Chung Hsing University
Director, Graduate Institute of Global Business and Strategy, National Taiwan Normal University (NTNU)
Director/CEO, Center for Global Innovation and Entrepreneurship, NTNU
Fulbright Visiting Scholar, USA
Director
Yu-Lung Lin
Education
University of Southern California(USC), MBA
National Chengchi University, MBA
CFA, FRM, CPA
Experience
Supervisor , Deloitte & Touche Leader.
Supervisor of the OTC department, Taipei Exchange(TPEx).
Vice President of underwriting syndicate , SinoPac Securities.
Vice President, Vincera Capital.
Director & Vice President of underwriting syndicate, Fubon Securities Co.
Director & Executive Vice President, Fubon Securities Venture Capital Co.
Director
Morrison Capital Investment Co., Ltd.,
Representative / Yen-Chao YangEducation
Tunghai University, Bachelor of Landscape Architecture
Experience
PM, JiaXing Sanwa Yoshida Building Materials Co., LTD.
Chairman, Morrison Capital Investment Co., Ltd.
Chairman, MARX Biotech Co., Ltd.
General Manager & Deputy Spokesperson, MARX Biotech Co., Ltd.
Director
Morrison Capital Investment Co., Ltd.,
Representative / Wei-Lun WengEducation
National Chengchi University, Bachelor of Laws
Judicial Special Examination (Judge Qualification), 2001
Attorney Examination (Lawyer Qualification), 2001
Experience
Prosecutor, Taiwan Taoyuan District Prosecutors Office
Prosecutor, Taiwan Shihlin District Prosecutors Office
Delegated Prosecutor, Agency Against Corruption, Ministry of Justice
Supervisor, Lecagen Regenerative Technology Co., Ltd.
Supervisor, Shin Kong No. 1 REIT
Director
Min-Chu Huang
Education
Takushoku University, Tokyo,Japan, MBA
Experience
General Manager, Taipei Exchange (TPEx)
Chairman, SinoPac Securities Co., Ltd.
President, Taiwan Securities Association
Adjunct Professor, Department of Accounting, National Chengchi University
Adjunct Professor, Department of Business Administration, National Taipei University
Independent Director, Merdury Biopharmaceutical Co., Ltd.
Independent Director
Chun-Hung Yang
Education
Ph.D. in Economics, Xiamen University
Master of Business Administration, National Taipei University
Bachelor of Business Administration, National Sun Yat-sen University
Experience
Senior Vice President, Financial Management Group, Fubon Financial Holding Co., Ltd.
Director & Senior Vice President, Fubon Securities Co., Ltd.
Chairman, Fubon Futures Co., Ltd.
Director, Fubon Securities Investment Trust Co., Ltd.
Director, Taiwan Futures Exchange Corp.
Advisor, Fubon Securities Co., Ltd.
Independent Director
Chi-Hsiang Chen
Education
University of Texas at Austin, Ph.D. in Microbiology
Executive Master's Program in Technology Management, Graduate Institute of Business Administration, National Chengchi University
Master of Science in Agricultural Chemistry, National Taiwan University
Experience
Senior Vice President, Maxigen Biotech Inc.
General Manager, Taiwan Leader Biotech Corp.
Chairman & General Manager, UBI Pharma Inc.
Independent Director
Chia-Lin Hsu
Education
Ph.D. in Immunology, Duke University, USA
Master, Institute of Microbiology and Immunology, National Yang-Ming University
B.S., Department of Zoology, National Taiwan University
Experience
Postdoctoral Researcher in Immunology, Genentech, USA
Senior Scientist, Center for Therapeutic Innovation, Pfizer
Assistant Professor & Associate Professor, Institute of Microbiology and Immunology, National Yang-Ming University
Deputy Secretary-General, Chinese Society of Immunology
Taiwan Representative, International Union of Immunological Societies (IUIS)
Head of R&D Division, Head of Administration Division & Deputy Director, Laboratory Animal Center, National Yang Ming Chiao Tung University
Audit Committee
The Audit Committee of the Company consists of all Independent Directors. It convenes meetings at least once every quarter and may hold additional meetings as necessary. The powers and responsibilities of the Audit Committee are as follows:
- In accordance with Article 14-1 of the Securities and Exchange Act, companies are required to establish or amend internal control systems.
- Assessment of the Effectiveness of Internal Control Systems.
- Adoption or amendment, pursuant to Article 36-1 of the Securities and Exchange Act of handling procedures for financial or operational actions of material significance, such as acquisition or disposal of assets, derivatives trading, loaning of funds to others, and endorsements or guarantees for others.
- Matters concerning the personal interests of the Directors.
- Significant asset or derivative transactions.
- Significant capital loans, endorsements, or guarantees.
- The offering, issuance, or private placement of any equity-type securities.
- Appointment, termination, or compensation of Certified Public Accountants (CPAs).
- The appointment or discharge of a financial, accounting, or internal audit officer.
- Annual financial reports and second quarter financial reports signed by the Board of Director, Managers, and Accounting Manager and audited by CPA.
- Other significant matters as required by other Companies or regulatory authorities.
Remuneration Committee
The Compensation Committee consists of three members appointed by resolution of the Board of Directors, with a majority of its members required to be Independent Directors The committee is required to hold at least two meetings per year and is responsible for fulfilling the following duties with due care and diligence, and submitting their recommendations to the Board of Directors for discussion:
- Regularly review this regulation and propose any amendment suggestions.
- Establish and regularly review performance evaluation standards, annual long-term performance goals and policies, systems, standards, and structures for the compensation for Directors, supervisors, and managers. The content of the performance evaluation standards shall be disclosed in the annual report.
- Regularly assess the performance goals achieved by the Directors, supervisors, and managers of the Company. Based on the evaluation results obtained from the performance evaluation criteria, determine the content and amount of their individual salary compensation. The annual report shall disclose the individual performance evaluation results of Directors, Supervisors, and Managers, as well as the correlation and reasonableness of their individual compensation packages in relation to the evaluation results, which shall also be reported at the shareholders' meeting.
Internal Audit
The Audit Department of the Company operates under the authority of the Board of Directors. Its primary purpose is to assist the Board of Directors and management by examining and evaluating deficiencies in the internal control system, as well as assessing the effectiveness and efficiency of operations. Additionally, it offers timely recommendations to management for enhancing the system and ensuring the ongoing and efficient implementation of the internal control system. This enables the optimal utilization of corporate resources, improves operational integration efficiency, and aids management in fulfilling their responsibilities. Additionally, it supports management in fulfilling their responsibilities and serves as a basis for reviewing and modifying the internal control system.
Articles of Incorporation
Rules of Procedure for Shareholders' Meetings
Rules of Procedure for Board of Directors Meetings
Procedures for Election of Directors
Audit Committee Organizational Charter
Remuneration Committee Organizational Charter
Regulations for Board Performance Evaluation
Code of Ethical Business Conduct
Procedures and Guidelines for Ethical Business Operations
Code of Ethical Conduct
Corporate Governance Best Practice Principles
Contact IR Information
Deputy Spokesperson
Carol Chien
Fax
(02)2243-9543